| 摘要 |
This invention pertains to a liquid intranasal pharmaceutical formulation comprising a pharmaceutically acceptable acid addition salt of rotigotine and alpha-cyclodextrin, preferably in the form of a buffered aqueous solution having a viscosity of 0.5-1.5 mm<SUP>2</SUP>/s
|
